Healthcare Industry News: abdominal aortic aneurysm
News Release - September 3, 2008
Six-Year Follow-up Data Confirms Endologix Powerlink's Outstanding Durability and OutcomesIRVINE, Calif.--(HSMN NewsFeed)--Endologix, Inc. (Nasdaq:ELGX ) today announced that six-year patient follow-up data from the Company’s Powerlink® System pivotal clinical trial supporting the durability of the Powerlink System as a minimally invasive treatment for abdominal aortic aneurysm (AAA) was published in the peer-reviewed Journal of Vascular Surgery (September 2008). A link to the abstract “The Powerlink System for endovascular abdominal aortic aneurysm repair: Six-year results” is available at www.endologix.com.
Highlights from the six-year follow-up of patients treated with the Powerlink System include:
- 97.9% freedom from AAA mortality
- Excellent device performance and integrity, with no ePTFE graft failures, no stent fractures, no aneurysm ruptures
- Remarkably low incidence of secondary procedures to treat Type I endoleak (3.1%) or a limb occlusion (1.6%)
- No migration in patients who received the device via an anatomical fixation technique
- Significant aneurysm sac diameter reduction in 83% of patients
Endologix President and CEO John McDermott said, “We are pleased with the continued clinical performance of the Powerlink System and the growing body of evidence that demonstrates long-term durability and positive outcomes. In the months ahead, we will be introducing new devices and supporting clinical data that further expand the number of patients that can be treated with the Powerlink System.”
Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix’s Web site at www.endologix.com.
Except for historical information contained herein, this news release contains forward-looking statements relating to the introduction of new products and continuing clinical results obtained with the Powerlink System, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2007, and the Company’s other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.